|Bid||2.05 x 800|
|Ask||2.06 x 3100|
|Day's Range||2.04 - 2.07|
|52 Week Range||1.02 - 27.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.70|
In June, the Committee for Medicinal Products for Human Use recommended a favorable opinion on the approval of Puma Biotechnology’s (PBYI) Nerlynx for its commercialization in the European Union for the prolonged adjuvant therapy of adults with early-stage HER2+ (hormone-receptor-positive) breast cancer whose prior adjuvant trastuzumab-based therapy is less than one year from completion.
On a per-share basis, the London-based company said it had a loss of 48 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.08. A year ago, they were trading at $22.89. _____ ...
Pipeline expanded with gene therapy technologies including AXO-Lenti-PD for treatment of Parkinson’ s Disease and AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy Ilise Lombardo, MD, promoted ...
Short interest is low for AXON with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.
Investors in Axovant Sciences (AXON) need to pay close attention to the stock based on moves in the options market lately.
Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Axovant Sciences' (AXON) shares gain, following the news of a licensing deal for oculopharyngeal muscular dystrophy candidate with Benitec Biopharma.
Axovant and Benitec Biopharma Rise on Gene Therapy Licensing DealAxovant and Benitec Biopharma enter into a licensing deal
Shares of the biopharmaceutical company rose 5% in early morning trading Monday after it announced it had bought the rights to a new gene therapy treatment designed for a rare form of muscular dystrophy from Benitec Biopharma Ltd. Axovant rose 12 cents -- or 5% -- to $2.68 a share on news of the deal while Benitec skyrocketed $1.52 -- or 67.8% --$3.76. The two companies also entered into a research collaboration to develop five more treatments meant to target neurological disorders.
Axovant Sciences (AXON) today announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of oculopharyngeal muscular dystrophy (OPMD), and has also entered into a research collaboration for the development of five additional gene therapy products in neurological disorders. The Silence-and-Replace gene therapy technology is designed to deliver a combination of DNA-directed RNA interference (silence) along with a functional copy of the gene (replace) in a single vector construct.
Roivant Sciences, which raised $1.1 billion in equity last summer from the SoftBank Vision Fund and Founders Fund, has confirmed a round of layoffs. According to a prepared statement, the New York-based company said there has been a reduction in headcount of less than 10 percent of all employees. The announcement comes as the company also outlined that it has created two new business units — Roivant Pharma and Roivant Health.
Axovant Sciences (AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first annual Roivant Pipeline Day on July 10, 2018 at 4:30 p.m. ET. A live webcast will be available in the Investors section of Axovant's website at www.axovant.com. Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.
Axovant Sciences (AXON) and Oxford Biomedical aim to develop AXO-Lenti-PD gene therapy as a long-term treatment for PD (Parkinson’s disease). Once administered using MRI1-guided stereotactic delivery, this gene therapy could help reduce motor fluctuations resulting from depleting dopamine levels in the brain.
Between March 31 and June 8, Axovant Sciences (AXON) stock rose ~284% from $1.69 to $4.80, largely due to the company’s entry into lentiviral vector gene therapy for PD (Parkinson’s disease) through a licensing arrangement with Oxford BioMedica. Axovant Sciences has secured worldwide development and commercialization rights for its investigational therapy, AXO-Lenti-PD, which aims to restore dopamine in the striatum of PD patients’ brain.
Axovant Sciences (AXON) stock rose 150% in the week of June 1–8. Over the last quarter, Axovant Sciences stock has risen 192.7%. On June 6, Axovant Sciences entered into a licensing agreement for worldwide rights to develop and sell Oxford BioMedica’s OXB-102 investigational gene therapy for the treatment of Parkinson’s disease.
As a micro-cap company, Axovant Sciences Ltd (NASDAQ:AXON) is naturally fraught with risks. The company is losing money and debt levels are elevated at 0.49 times equity. AXO-Lenti-PD is a gene therapy for treating Parkinson’s disease.
Axovant Sciences Ltd’s (NASDAQ:AXON): Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United StatesRead More...